调强放疗时代儿童鼻咽癌中诱导或辅助化疗联合同步放化疗对比单纯同步放化疗:基于EBV DNA的递归分割风险分层分析
该研究纳入2005至2021年诊断的549例儿童鼻咽癌患者,比较诱导或辅助化疗联合同步放化疗与单纯同步放化疗的预后及不良反应,主要终点为无进展生存期(PFS)。基于递归分割分析(RPA)建立风险分层系统,识别出三个风险组。中危组(IVa期且EBV<4000拷贝/ml)接受诱导化疗后同步放化疗者的3年PFS率显著优于单纯同步放化疗者(87.35% vs 75.89%,P=0.04),但低危组或高危组未从额外化疗中获得生存获益;联合化疗组3/4级中性粒细胞减少和白细胞减少发生率显著更高。
要点
- RPA风险分层系统将儿童鼻咽癌分为低危、中危和高危三组。
- 中危组(IVa期且EBV<4000拷贝/ml)诱导化疗后同步放化疗较单纯同步放化疗显著改善3年PFS(87.35% vs 75.89%,P=0.04)。
- 低危和高危组未从诱导或辅助化疗中获得生存获益,且联合化疗组3/4级血液学不良反应发生率更高。
核心结论
- 中危组(IVa期且EBV<4000拷贝/ml)儿童鼻咽癌患者接受诱导化疗后同步放化疗较单纯同步放化疗有显著更好的PFS。
- 诱导或辅助化疗联合同步放化疗的急性不良反应总体发生率高于单纯同步放化疗。
研究设计与样本
- 研究纳入2005至2021年诊断的549例儿童鼻咽癌患者。
- 主要终点为无进展生存期(PFS)。
- 采用递归分割分析(RPA)建立风险分层系统,用Kaplan-Meier法评估累积生存率,Cox分析评估变量与终点的关系。
主要发现
- RPA风险分层识别出三个不同的风险组。
- 中危组(IVa期且EBV<4000拷贝/ml)接受诱导化疗后同步放化疗者的3年PFS率为87.35%,单纯同步放化疗者为75.89%,差异有统计学意义(P=0.04)。
- 低危组(II-III期且EBV<4000拷贝/ml)和高危组(II-IVa期且EBV≥4000拷贝/ml)未从额外诱导或辅助化疗中获得生存获益。
- 单纯同步放化疗、诱导化疗+同步放化疗、同步放化疗+辅助化疗组最常见的3或4级不良事件分别为中性粒细胞减少(8.1%、33.0%、36.9%)和白细胞减少(14.1%、26.8%、32.3%),差异有统计学意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the prognosis and adverse effects of induction or adjuvant chemotherapy (IC or AC) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in paediatric nasopharyngeal carcinoma (NPC) patients in the intensity-modulated radiotherapy (IMRT) era. METHODS AND MATERIALS: 549 patients diagnosed from 2005 to 2021 were enrolled. Our primary endpoint was progression-free survival (PFS). The recursive partitioning analysis (RPA) was applied to derive a risk stratification system. Kaplan-Meier survival curves were used to assess the cumulative survival rates, and cox analysis was applied to evaluate the relationship between variables and endpoints. RESULTS: The RPA-based risk stratification identified three different risk groups. In the intermediate-risk (stage IVa and EBV<4000 copies/ml) group, patients who received IC followed by CCRT achieved a significantly better 3-year PFS rate than those treated with CCRT alone (87.35% versus 75.89%; P = 0.04). But survival benefit was not obtained from the additional IC or AC in the low-risk (stage II-III and EBV<4000 copies/ml) or high-risk (stage II-IVa and EBV≥4000 copies/ml) group. The most common grade 3 or 4 adverse events in patients treated with CCRT, IC + CCRT, and CCRT + AC were neutropenia (8.1%, 33.0% versus 36.9%, respectively) and leukopenia (14.1%, 26.8% versus 32.3%, respectively) with statistically significant difference. CONCLUSIONS: Paediatric NPC patients in the intermediate-risk group treated with IC followed by CCRT had significantly better PFS compared with patients treated with CCRT alone. And the overall incidence of acute adverse events in patients treated with IC or AC plus CCRT was higher than in patients treated with CCRT alone.
引用
- Liang YJ, Wen DX, Luo MJ, et al. Induction or adjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in paediatric nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA. Eur J Cancer. 2021. PMID: 34743068. doi:10.1016/j.ejca.2021.09.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。